Clinical Trial Design: Implications of Value-based Oncology Frameworks
The rising cost of oncology drugs has been drawing increasing questions from payers, providers and regulators about the relative value of individual therapies and how to quantify that value in light of pricing trends. Some even argue that these prices are unjustified.
In response, several healthcare industry organizations have been developing value frameworks in attempt to assign a quantitative value to these drugs and to determine whether that value corresponds to their market cost. One of the most prominent tools to emerge from this trend is the American Society of Clinical Oncology’s (ASCO) Value Framework.
Read a perspective from QuintilesIMS’s John Doyle, Senior Vice President, Advisory Services, on the implications of value-based oncology frameworks on clinical trail design. Read John’s Blog here.
For further content relating to oncology trials please click here.